A Phase II Study of Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
University of Utah
Summary
The purpose of this clinical trial it to test the safety and tolerability of the study drugs mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Subjects aged ≥ 18 years with documented diagnosis of WM with the definition of measurable disease * Subjects who are able to comply with the study protocol. * Subjects with relapsed or refractory WM who have received at least one prior line of therapy. * Must have received prior treatment with covalent BTK inhibitor or have declined such treatment. * Prior autologous stem cell transplant is permitted if completed ≥ 100 days prior to treatment. * Prior allogeneic transplants are not permitted. * Subjects must have an indication for treatment per 2nd International…
Interventions
- DrugPirtobrutinib
200 mg daily
- DrugMosunetuzumab
Administered subcutaneously on day one of applicable cycles.
Location
- Huntsman Cancer Institute at University of UtahSalt Lake City, Utah